CompletedPhase 1NCT00078637

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Studying Lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eisai Inc.
Principal Investigator
Jantien Wanders, M.D.
Eisai Inc.
Intervention
E7820(drug)
Enrollment
37 target
Eligibility
18 years · All sexes
Timeline
20042007

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00078637 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma

← Back to all trials